• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.

    5/15/25 8:15:55 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care
    Get the next $NPCE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    NeuroPace Inc

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    641288105

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    641288105


    1Names of Reporting Persons

    OrbiMed Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,406,335.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,406,335.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,406,335.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.5 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    641288105


    1Names of Reporting Persons

    OrbiMed Capital GP VI LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,406,335.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,406,335.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,406,335.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.5 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NeuroPace Inc
    (b)Address of issuer's principal executive offices:

    455 N. Bernardo Avenue Mountain View, CA 94043
    Item 2. 
    (a)Name of person filing:

    OrbiMed Advisors LLC OrbiMed Capital GP VI LLC
    (b)Address or principal business office or, if none, residence:

    601 Lexington Avenue, 54th Floor New York, NY 10022
    (c)Citizenship:

    Please refer to Item 4 on each cover sheet for each filing person.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    641288105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    OrbiMed Advisors LLC: 3,406,335 OrbiMed Capital GP VI LLC: 3,406,335
    (b)Percent of class:

    OrbiMed Advisors LLC: 10.5% OrbiMed Capital GP VI LLC: 10.5%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    OrbiMed Advisors LLC: 0 OrbiMed Capital GP VI LLC: 0

     (ii) Shared power to vote or to direct the vote:

    OrbiMed Advisors LLC: 3,406,335 OrbiMed Capital GP VI LLC: 3,406,335

     (iii) Sole power to dispose or to direct the disposition of:

    OrbiMed Advisors LLC: 0 OrbiMed Capital GP VI LLC: 0

     (iv) Shared power to dispose or to direct the disposition of:

    OrbiMed Advisors LLC: 3,406,335 OrbiMed Capital GP VI LLC: 3,406,335

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Reporting Persons hold 10.5% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC exercises investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    OrbiMed Advisors LLC
     
    Signature:/s/ Carl L. Gordon
    Name/Title:Carl L. Gordon / Member
    Date:05/15/2025
     
    OrbiMed Capital GP VI LLC
     
    Signature:/s/ Carl L. Gordon
    Name/Title:Carl L. Gordon / Member of OrbiMed Advisors LLC
    Date:05/15/2025
    Get the next $NPCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NPCE

    DatePrice TargetRatingAnalyst
    5/28/2025$18.00Buy
    H.C. Wainwright
    1/21/2025$17.00Buy
    UBS
    3/14/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$22.00Outperform
    Leerink Partners
    11/10/2023$11.00Overweight
    Cantor Fitzgerald
    8/24/2023$5.00 → $6.00Underweight → Equal-Weight
    Morgan Stanley
    2/22/2023$10.00Buy
    Lake Street
    4/6/2022$13.00Outperform
    Wolfe Research
    More analyst ratings

    $NPCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      11/14/24 6:30:12 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      11/14/24 3:36:16 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      10/3/24 4:46:48 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 1% to 105,338 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:12 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • CHIEF FINANCIAL OFFICER Kuhn Rebecca covered exercise/tax liability with 357 shares, decreasing direct ownership by 0.27% to 132,950 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:09 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 357 shares, decreasing direct ownership by 0.41% to 87,281 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:06 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Financials

    Live finance-specific insights

    See more
    • NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

      -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

      5/27/25 8:00:00 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Reports First Quarter 2025 Financial Results

      -- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. Recent Highlights Revenue g

      5/13/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Provides Update on Tariff Status

      -- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its operations and financial results. Specifically, NeuroPace manufactures and sells the vast majority of its devices in the United States and has limited supply chain activities outside th

      4/14/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

      -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

      5/27/25 8:00:00 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Reports First Quarter 2025 Financial Results

      -- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. Recent Highlights Revenue g

      5/13/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Provides Update on Tariff Status

      -- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its operations and financial results. Specifically, NeuroPace manufactures and sells the vast majority of its devices in the United States and has limited supply chain activities outside th

      4/14/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    SEC Filings

    See more
    • Neuropace Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NeuroPace Inc (0001528287) (Filer)

      5/27/25 8:09:45 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.

      SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)

      5/15/25 8:15:55 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Neuropace Inc.

      10-Q - NeuroPace Inc (0001528287) (Filer)

      5/13/25 5:15:48 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on NeuroPace with a new price target

      H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00

      5/28/25 9:08:28 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on NeuroPace with a new price target

      UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00

      1/21/25 8:23:18 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously

      3/14/24 8:11:10 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Leadership Updates

    Live Leadership Updates

    See more
    • NeuroPace Continues to Strengthen Management Team

      MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments

      10/16/24 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Strengthens Management Team with Two Key Appointments

      Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma

      9/4/24 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Announces CEO Transition

      NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four years as President, CEO and Board Member and will continue to advise through transition MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023. Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace'

      6/28/23 4:03:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care